Risks of gene therapy should be weighed against lack of alternatives for many diseases

doi:10.1136/bmj.330.7494.791-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Robert E MacLaren, MRC research fellow,
Robin R Ali, professor of human molecular genetics,
Adrian J Thrasher, professor of paediatric immunology

Division of Molecular Therapy, Institute of Ophthalmology, University College London, London EC1V 9EL
Molecular Immunology Unit, Institute of Child Health, UCL, London WC1N 1EH

EDITOR—Kimmelman provided a comprehensive discussion about the risks and ethics of gene therapy.1 We certainly cannot predict the future, but the risks should be weighed against the complete lack of alternative options for many of the diseases discussed.